30
Participants
Start Date
September 1, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
November 30, 2025
HB0052 Injection
An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload
Peking University Cancer Hospital, Beijing
Peking University Cancer Hospital & Institute
OTHER
Zhejiang Cancer Hospital
OTHER
Shandong Cancer Hospital and Institute
OTHER
Hunan Cancer Hospital
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
The Second Affiliated Hospital of Harbin Medical University
OTHER
Huazhong University of Science and Technology
OTHER
Shanghai Huaota Biopharmaceutical Co., Ltd.
INDUSTRY